Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-20

Study Completion Date

2022-09-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Data concerning the effectiveness od nutraceuticals in children with dyslipidemia are lacking. The aim of the present study was to evaluate the efficacy and safety of the long-term use of a dietary supplement containing red yeast rice (RYR), combined with other natural compounds, in children and adolescents with hypercholesterolemia.

A nutraceutical, containing RYR, polycosanols, coenzyme Q10, astaxanthin and folic acid (commercial name: Armolipid), was administered once-daily in 84 children/adolescents with moderate or severe hypercholesterolemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Addition of Whole Grains to the Diets of Middle-school Children

NCT01094652

Healthy

COMPLETED NA

Effects of Wholegrains on Children's Health (KORN)

NCT04430465

Cardiometabolic Health Gastro-intestinal Wellbeing Cognitive Function +1 more

COMPLETED NA

Vitamin A Equivalence of Plant Carotenoids in Children

NCT00680212

Vitamin A Deficiency

COMPLETED PHASE2

Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations.

NCT00248716

Iron Deficiency Anemia

UNKNOWN PHASE4

Efficacy of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia

NCT02257762

Child Malnutrition

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective single center cohort study conducted at Outpatient Lipid Unit of 2nd Department of Pediatrics of the National and Kapodistrian University of Athens at the "Panagiotis \& Aglaia Kyriakou" Children's Hospital in Greece. The study complies with the Declaration of Helsinki and the protocol was reviewed and approved by the appropriate ethical committee. Parental informed written consent was obtained prior to enrollment.

Study population: Ninety children and adolescents, aged 7 to 16 years, with primary dyslipidemia.

All participants had a positive family history for hypercholesterolemia (LDL \> 95th percentile) and most of them had a positive family history for premature CVD (\<55 years for males and \<60 years for females) in first or/and second-degree relatives. Eleven of them had a genetically confirmed diagnosis of HeFH, while the rest had a probable or positive HeFH according to the Dutch Lipid Clinic Network criteria. None of them had moderate or significant hypertriglyceridemia, even those with increased body mass index (BMI).

All children followed a low saturated fat and low cholesterol diet by a trained dietician and had moderate or intense physical activity, for at least 6 months before the participation in the study. In addition, during the last 6 months, 19 of them consumed 1.5 - 2.5g of plant sterols daily in the form of a yogurt drink or spread. Lifestyle and eating habits were maintained throughout the study.

A nutraceutical containing five natural substances formulated as a tablet with the commercial name Armolipid (Rottapharm S.p.A., Monza, Italia), was recommended in all participants. Every tablet contained 200 mg red yeast rice (RYR) extract equivalent to 3 mg of monacolin K, 10 mg policosanols, 0.2 mg folic acid, 2.0 mg coenzyme Q10 and 0.5 mg astaxanthin, and was citrinin-free. It was administered once-daily with lunch.

All participants as well as their parents were interviewed using a data collection form, created specifically for this research. Details concerning compliance to supplement intake, as well as possible adverse effects were recorded and analysed. Six out of 90 children were excluded from the study because they did not comply with the recommendation for taking the supplement (compliance rate 93.3%). All the rest 84 children had one and 64 of them had two evaluations under Armolipid treatment.

Clinical and Labolatory evaluation: A clinical and laboratory evaluation of all participants took place right before (Time 0, T0) and once (n=84, Time 1, T1) or twice (n=64, T1 and Time 2, T2) after the start of nutraceutical supplementation.

The body weight (BW) in kg, the height (H) in cm were measured to the nearest 0.1 kg and 0.5 cm, respectively (TANITA, Corporation Tokyo), with children barefoot and lightly dressed. BMI was calculated as BW in kg per H in m2. The standard deviation scores (z-scores) of BW, H and BMI were also calculated according to a standardized age- and sex- specific calculator. Waist circumference (WC) in cm was measured and the ratio of WC/Height was calculated. Systolic (SBP) and diastolic blood pressure (DBP) in mmHg were measured three consecutive times using an automated oscillometric device (Dinamap V100, GE Medical Systems Information Technologies) and the average value of the three measurements was used in the statistical analysis. The stage of puberty was recorded according to Tanner stages (I-V) for boys and girls.

A full lipid profile including TC, LDL-C, high density lipoprotein - cholesterol (HDL-C), non-high density lipoprotein - cholesterol (non-HDL-C), triglycerides (TGs), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) \[Lp(a)\] levels was evaluated in serum, after an overnight fast. Serum creatinine, glucose, aspartate and alanine aminotransferases (AST and ALT), creatine kinase (CK), and thyroid-stimulating hormone (TSH) were also assessed. A full blood count was performed in all participants.

TC, HDL-C, LDL-C, TGs, glucose, ALT, AST, CK and creatinine were measured using an enzymatic method (Roche Diagnostics) on an automatic analyzer (Cobass Integra 800), and Apo-A1, Apo-B, and Lp(a) by an immunonephelometric assay (Siemens BNII Nephelometer Analyzer), with an intra-assay and inter-assay variation \<5% for all tests. Non-HDL-C was measured as TC minus HDL-C. All lipid values are expressed in mg/dL. Haematological parameters (full blood count) were analyzed using the SysmexXE-2100 automated haematology analyzer (Roche Diagnostics). All tests were performed according to the manufacturers' instructions.

At the time of the examination, all children were healthy and none of them had a febrile or afebrile infection in the two weeks preceding the check-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemias Children, Only

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Armolipid

One tablet of Armolipid (Rottapharm S.p.A., Monza, Italia), containing 200 mg red yeast rice, 10 mg policosanols, 0.2 mg folic acid, 2.0 mg coenzyme Q10 and 0.5 mg astaxanthin was administered once-daily with lunch.

Clinical and laboratory evaluation took place before and 6 (IQR: 5-8) and 16 (IQR: 11-19.7) months after treatment.

Group Type EXPERIMENTAL

Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia

Intervention Type DIETARY_SUPPLEMENT

A prospective single center cohort study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.